To evaluate the prognostic value of early postoperative prostate-specific antigen (PSA) levels after RP in patients with lymph node invasion (LNI). The study included 319 prostate cancer patients with LNI who were treated with RP and extended pelvic ... [...]
7, 2016) — In the 30 years since the U.S. Food and Drug Administration (FDA) approved the prostate specific antigen (PSA) test as the primary screening method to detect prostate cancer, the mortality rate for men diagnosed with the disease has ... [...]
Multiple biomarkers are needed to distinguish aggressive from indolent prostate cancer. We tested the prognostic utility of a three-marker fluorescent in situ hybridization panel (TMPRSS2/ERG rearrangements, AR gain, and PTEN deletion) in a ... [...]
This was a multi-institutional, non-blinded, single-arm phase II trial (NCT00734851) conducted through the Department of Defense Prostate Cancer Clinical Trials Consortium (DOD PCCTC) across three trial sites. Eligibility included men with prostate ... [...]
San Francisco, CA USA (UroToday.com) Dr. Robert Bristow of the Princess Margaret Cancer Centre in Toronto presented data from work by the International Cancer Genome Consortium that attempted to characterize patients by molecular patterns to allow ... [...]
When prostate cancer screening became de rigeur in the 1990s, doctors didn't realize that most of the lesions they would find would not actually need treatment. Studies now suggest that about half of men diagnosed with prostate cancer are over ... [...]
“Prostate cancer is not discerning. It doesn't just hit the bad guys; it's the good guys as well. I've got friends such as Sky Sports rugby league colleagues Bill Arthur and Eddie Hemmings who I have known longer than I care to remember. Both are great ... [...]
A: The types of second cancers that are more prominent are actually the cancer types that are most common to start with. These include prostate cancer, lung cancer and colorectal cancer in men, and breast cancer, lung cancer and colorectal cancer in ... [...]
This Phase 3 clinical trial is expected to enroll approximately 450 patients with newly diagnosed low-grade prostate cancer who are candidates for active surveillance, but nonetheless are planning to undergo radical prostatectomy. This multi-center ... [...]